# Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

> **NCT05388149** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 15 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Neratinib

## Key facts

- **NCT ID:** NCT05388149
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-06
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388149, "Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05388149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*